



Non-coding RNA Based Therapeutic Vaccines

Guest Editors:

Dr. Ramar Thangam

**Prof. Dr. Ramasamy
Paulmurugan**

Dr. Heemin Kang

Deadline for manuscript
submissions:

closed (31 October 2022)

Message from the Guest Editors

Therapeutic targeting of RNA modulation has become a promising strategy for treating various types of disease, with emerging fields of noncoding-RNA-based therapeutics attracting the interest of biomedical research. The Special Issue focuses explicitly on obstacles associated with specificity, delivery, and tolerability, and promises of targeting miRNA, long noncoding RNA, PIWI-interacting RNAs (piRNAs), circRNAs, and siRNA for different therapeutic modalities discussed in human diseases. We also invite papers to describe novel ex vivo methods based on human cells, tissues, virological diseases, and other infectious disease agents that could help to bridge the gap between in vivo models and biomedical applications.

In summary, we sincerely hope that this Special Issue may serve as a valuable platform for exchanging the latest developments in noncoding-RNA-based clinical therapeutics, which will likely focus on promising emerging approaches that aim to boost their success toward next-generation therapy for human diseases.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com